European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice

DC ElementWertSprache
dc.contributor.authorJohansen, Jeanne D.
dc.contributor.authorAalto-Korte, Kristiina
dc.contributor.authorAgner, Tove
dc.contributor.authorAndersen, Klaus E.
dc.contributor.authorBircher, Andreas
dc.contributor.authorBruze, Magnus
dc.contributor.authorCannavo, Alicia
dc.contributor.authorGimenez-Arnau, Ana
dc.contributor.authorGoncalo, Margarida
dc.contributor.authorGoossens, An
dc.contributor.authorJohn, Swen M.
dc.contributor.authorLiden, Carola
dc.contributor.authorLindberg, Magnus
dc.contributor.authorMahler, Vera
dc.contributor.authorMatura, Mihly
dc.contributor.authorRustemeyer, Thomas
dc.contributor.authorSerup, Jorgen
dc.contributor.authorSpiewak, Radoslaw
dc.contributor.authorThyssen, Jacob P.
dc.contributor.authorVigan, Martine
dc.contributor.authorWhite, Ian R.
dc.contributor.authorWilkinson, Mark
dc.contributor.authorUter, Wolfgang
dc.date.accessioned2021-12-23T16:24:16Z-
dc.date.available2021-12-23T16:24:16Z-
dc.date.issued2015
dc.identifier.issn01051873
dc.identifier.urihttps://osnascholar.ub.uni-osnabrueck.de/handle/unios/14829-
dc.description.abstractThe present guideline summarizes all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed-type hypersensitivity skin and mucosal conditions. Sections with brief descriptions and discussions of different pertinent topics are followed by a highlighted short practical recommendation. Topics comprise, after an introduction with important definitions, materials, technique, modifications of epicutaneous testing, individual factors influencing the patch test outcome or necessitating special considerations, children, patients with occupational contact dermatitis and drug eruptions as special groups, patch testing of materials brought in by the patient, adverse effects of patch testing, and the final evaluation and patient counselling based on this judgement. Finally, short reference is made to aspects of (continuing) medical education and to electronic collection of data for epidemiological surveillance.
dc.description.sponsorshipIFRA; RIFM; NovartisNovartis; GSKGlaxoSmithKline; Vifor; Intendis - BayerBayer AG; Uriach PharmaDexcel Pharma; GenentechRoche HoldingGenentech; MenariniMenarini Group; MSD; AlmirallAlmirall; Biogen-IdecBiogen; Galderma; SmartPractice; Almirall HermalAlmirall; GlaxoSmithKlineGlaxoSmithKline; Basilea; Zilverlon; Stallergenes; UnileverUnilever; l'ARCAA; KAK, JDJ, AC, CL, ML, MM, JS, IRW: No conflicts. TA: Giving talks at meetings arranged by Leo Pharma and GlaxoSmithKline; KEA: Advisor to SmartPractice, Hillerod. Medical Director for Dermatological Investigation (DIS). Research support from IFRA and RIFM; AB: Educational grants from Novartis, GSK, Vifor; MB: member of the REXPAN, collaboration with SmartPractice on metal allergens; AGA: Medical Advisor for Uriach Pharma, Genentech, Novartis research grants by Intendis - Bayer, Uriach Pharma, Novartis, educational activities sponsored by Uriach Pharma, Novartis, Genentech, Menarini, GSK, MSD, Almirall; MG: Participated in the EDEN study on fragrance allergy. Since January 2014 participatation in the National Advisory Board for NOVARTIS (omalizumab for urticaria). Lectures on immunology of psoriasis for Portuguese dermatologists paid by Janssen (2012/13); AG: Departmental service (contact allergy website) financially supported by cosmetic and a few pharmaceutical companies; lecture on allergic contact dermatitis from cosmetics for GSK; lectures to pharmacists and dermatologists on dermatological preparations (contact allergy, irritancy) for Fagron; SMJ: Lecture fees from Almirall, Biogen-Idec, Galderma; VM: Has received lecturing fees from SmartPractice, Almirall Hermal, GlaxoSmithKline, Basilea; TR: Grants for the department from Almirall, Novartis, Zilverlon, Stallergenes; RS: Shareholder and scientific adviser of the Polish representative of Chemotechnique Diagnostics; JPT: Sold a cobalt spot test to Smart Health, Az, USA; MV: Grants from GlaxoSmithKline, Unilever, l'ARCAA; MW: Attended a drug advisory board meeting for GlaxoSmithKline; WU: Accepted travel reimbursement and partly honorarium for presentations given to cosmetic industry (associations) by them. Lecture fee from Almirall Hermal for educational lectures on contact allergy.
dc.language.isoen
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofCONTACT DERMATITIS
dc.subjectADVERSE DRUG-REACTIONS
dc.subjectAllergy
dc.subjectBASE-LINE SERIES
dc.subjectcontact allergy
dc.subjectDermatology
dc.subjectguideline
dc.subjectNICKEL SULFATE
dc.subjectPARA-PHENYLENEDIAMINE
dc.subjectPARA-TERTIARY-BUTYLCATECHOL
dc.subjectpatch testing
dc.subjectPETROLATUM PREPARATION
dc.subjectPOSITIVITY RATIO
dc.subjectPROSPECTIVE MULTICENTER
dc.subjectREACTION INDEX
dc.subjectreview
dc.subjectTEST SENSITIZATION
dc.titleEuropean Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice
dc.typereview
dc.identifier.doi10.1111/cod.12432
dc.identifier.isiISI:000361478100001
dc.description.volume73
dc.description.issue4
dc.description.startpage195
dc.description.endpage221
dc.contributor.orcid0000-0001-6842-1360
dc.contributor.orcid0000-0002-6181-824X
dc.contributor.orcid0000-0001-5968-0555
dc.contributor.orcid0000-0001-9951-5896
dc.contributor.orcid0000-0001-7253-3461
dc.contributor.orcid0000-0002-3537-8463
dc.contributor.orcid0000-0003-3770-1743
dc.contributor.orcid0000-0002-7543-8299
dc.contributor.researcheridAAF-7145-2021
dc.contributor.researcheridAAM-6382-2021
dc.contributor.researcheridABD-8517-2020
dc.contributor.researcheridH-2117-2011
dc.contributor.researcheridG-1585-2012
dc.contributor.researcheridU-1162-2018
dc.identifier.eissn16000536
dc.publisher.place111 RIVER ST, HOBOKEN 07030-5774, NJ USA
dcterms.isPartOf.abbreviationContact Dermatitis
crisitem.author.orcid0000-0001-5406-9458-
crisitem.author.netidJoSw269-
Zur Kurzanzeige

Seitenaufrufe

16
Letzte Woche
0
Letzter Monat
0
geprüft am 18.05.2024

Google ScholarTM

Prüfen

Altmetric